Investor Presentation - CelGro

September 2016

ASX: OCC

Paul Anderson
Managing Director

ortho·cell

Disclaimer

This presentation prepared by Orthocell Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Company Overview

Delivering breakthrough products in regenerative medicine:

Cell therapies:

- ***Ortho-ATI®***. **World's first stem cell therapy to regenerate tendons**
- ***Ortho-ACI®***. **Next generation cartilage repair**
- **Actively engaging strategic partners in US and Japan**

Soft tissue repair device CelGro®:

- **First EU approval imminent**
- **Platform technology**
- **Highest quality collagen scaffold to enhance soft tissue and bone regeneration**

- **Deal ready – positioned for commercialisation of products and rapid growth**

Corporate Overview

Experienced team to execute

CEO	Paul Anderson	• Verigen • Genzyme • Biomet
CSO	Prof. Ming Hao Zheng	• Verigen • Genzyme • UWA
Executive Chairman	Dr Stewart Washer	• Cynata • Minomic
Director	Matt Callahan	• iCeutica Inc • Botanix Pharmaceuticals • Dimerix
Director	Prof. Lars Lidgren	• UN Bone and Joint Chair • Biomet • Uni. Lund
Director	Qui Xiao Zhoa	• Shenzhen Lightning Digital • Technology Co Ltd

Key Facts

ASX	OCC
Share Price	AU$0.41 (@14th Sept 2016)
Ordinary Shares on Issue	91.2 million
Market Cap	AU$37 million
Options & Warrants outstanding	21.2 million
Cash at bank	AU$5 million (@ 30 June 2016)

Shareholding Structure

Shareholders 3,050

Directors & Management ---- 30% 60% -------Top 20

Investment Opportunity

Soft Tissue Repair - Global Need & Opportunity

Age quake

- Musculoskeletal disorders are twice as common as cardio-vascular conditions
- Increased demand for safe, efficient, cost effective treatments
- Global soft tissue repair market - US$7B in 2013 expected US$10B by 2020



Compelling clinical evidence

- CelGro® - Highest quality pure collagen medical device
- Ortho-ATI® - 300 patients successfully treated - first to market

Big Pharma currently investing/partnering

- Focus on cell therapies and scaffolds/devices
- Orthocell sits across all these areas

Recent M&A Deals

- 2014 – Organogenesis acquired Dermagraft (Human Dermis Scaffold - Orthopaedic applications) for US $300MM
- 2013 – DSM acquires Kensey Nash (Orthopaedic applications) for US $360MM

CelGro®

Collagen Scaffolds

A Paradigm Shift in Soft Tissue Reconstruction

Celgro® is a pure collagen medical device manufactured by Orthocell to augment soft tissue and bone regeneration.



Ideal collagen scaffold qualities:

- Compatibility
- Guided tissue repair/ optimal tissue integration remodeling
- Tensile strength
- Versatility

Competitor limitations:

- Not fit for purpose
- Poor integration
- Limited applications

CelGro® has a unique design history:

- Regenerative medicine focus
- Meets needs of soft tissue reconstruction
- Fit for purpose

Dental Application









CelGro®

Collagen Scaffolds

Dental Opportunity

2 million

 # annual dental membranes used in conjunction with bone graft substitutes 1.

$800 million

Value of addressable market in dental *1.*

CelGro®

opportunity

- **Guided tissue repair**
- **Optimal tissue remodeling**
- **Better bone quality**

1. US, JP, EU & AUS - 2015

Tendon Application









Tendon Opportunity

650,000

 # annual rotator cuff procedures suitable for Celgro *1.*

$1.6 billion

Value of addressable market in rotator cuff surgeries *1.*

CelGro® opportunity

- **Guided tissue repair**
- **Optimal tissue remodeling**
- **Reduced surgical failure rates**

1. US, JP, EU & AUS

Pathway to Market



Near Term Regulatory Approvals - First CelGro® EU

Product	Current Applications/Study	Stage of Development			Regulatory Targets 2.	
		Discovery	Pre-clinical	Clinical	0-6 months	Thereafter
CelGro®	Dental, guided bone, soft tissue regeneration				**CE Mark** (EU)	**FDA** (US) **ARTG** (AUS)
	Rotator-cuff tendon repair					**CE Mark** (EU) **FDA** (US) **ARTG** (AUS)
	Peripheral nerve repair					**CE Mark** (EU) **FDA** (US)
	Cartilage repair					**CE Mark** (EU)
1. **Ortho-ATI®**	Tennis elbow, gluteal, patella, achilles & rotator-cuff					**PMDA** (JP) **PreIND** (US) **ARTG** (AUS)
1. **Ortho-ACI®**	Knee & ankle cartilage repair					**Asia Pacific ARTG** (AUS)
Pipeline	Ligament replacement - ACL, growth factors, lab grown tendon					**In development**

1. *Marketed in Australia, Singapore, Hong Kong and New Zealand*
2. *Orthocell's estimates for regulatory applications*

CelGro® - CE Mark

Collagen Scaffolds

CelGro® First EU approval -
guided bone regeneration and soft tissue reconstruction

What does it mean?

✓Authorised to market and distribute in the EU

✓EU approved manufacturing facility

Benefits of a CE Mark:

- Allows market entry in EU
- Foundation for regulatory application in other jurisdictions - US(FDA) and AU(ARTG)
- Platform technology validation

CelGro® - Platform

Collagen Scaffolds

Value Increases With Every Additional Application



12 Month Milestones - Lead Applications

Regulatory Targets

- EU approval for Dental application -

with regulatory applications in other jurisdictions to follow (US, AUS, JP)

- EU Tendon application -

with regulatory applications in other jurisdictions to follow (US, AUS, JP)

Clinical Studies

- Dental study completion and publication
- Patient recruitment completion, for tendon, cartilage and nerve studies

Strategic Partnering

- Partnering deals in EU, US and JP

ortho·cell

advancing tissue repair & regeneration

- Superior products
- Significant de-risked opportunity
- Clear pathway to large markets
- Expertise to partner and execute

Appendices

How CelGro® Works



Positioning CelGro®

	CelGro®	Biogide®	Tissuemend®	Osseoguard®	BioMend Extend®	GraftJacket®
Highest Quality Raw Material	✓	✗	✗	✗	✗	✗
Proven Compatibility	✓	+/-	+/-	+/-	+/-	+/-
Native Bilayer Structure	✓	✓	✗	✗	✗	✗
Strong Mechanical Properties	✓	+/-	✓	+/-	✓	✓
Versatile Platform	✓	✗	✗	✗	✗	✗

Ortho-ATI®

ortho·cell

Orthocell's Autologous Tenocyte Implantation

Ortho-ATI® is a stem cell therapy to regenerate tendons and ligaments which:

- uses each patient's own stem cells to regenerate tendon tissue
- enables healing of tendons, reduces pain and increases strength
- greatly improves the patient's mobility and quality of life
- multiple tendon applications

Ortho-ATI® is a two stage minimally invasive, walk-in, walk-out process:

- Biopsy procedure and tenocyte cultivation
- Cell implantation

- 4-5 week end to end process
- early symptomatic relief, followed by structural and functional improvements



Common sites for Ortho-ATI®

Ortho-ATI®

ortho·cell

Breakthrough Regenerative Medical Therapy

Market leading world first tendon regeneration treatment manufactured in Orthocell's TGA licensed facility

Over 300 patients treated to date. Demonstrated pathway to market

Non operative procedure with high cost-benefit outcomes

Directly addresses the underlying pathology of tendinopathy (disease modifying)

Patent protected in all major jurisdictions including USA, Australia, China, Singapore, Hong Kong and New Zealand



Expansion Plans

Validated pathway to market

- Referral pathway
- Treatment pathway
- Manufacturing optimisation
- Tech transfer ready

Bringing Ortho-ATI™ to the world's largest markets:

- IND being prepared for US Phase 2 tennis elbow study
- partnering discussions ongoing with US and EU potential partners
- discussions in Japan underway to leverage abridged approval process